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Open PHACTS computational protocols for in
silico target validation of cellular phenotypic
screens: knowing the knowns†‡
D. Digles,§*a B. Zdrazil,a J.-M. Neefs,b H. Van Vlijmen,b C. Herhaus,c A. Caracoti,d
J. Brea,e B. Roibás,e M. I. Loza,e N. Queralt-Rosinach,f L. I. Furlong,f A. Gaulton,g
L. Bartek,h S. Senger,h C. Chichester,ij O. Engkvist,k C. T. Evelo,l N. I. Franklin,m
D. Marren,n G. F. Eckera and E. Jacoby§*b
Phenotypic screening is in a renaissance phase and is expected by many academic and industry leaders to
accelerate the discovery of new drugs for new biology. Given that phenotypic screening is per definition
target agnostic, the emphasis of in silico and in vitro follow-up work is on the exploration of possible mo-
lecular mechanisms and efficacy targets underlying the biological processes interrogated by the phenotypic
screening experiments. Herein, we present six exemplar computational protocols for the interpretation of
cellular phenotypic screens based on the integration of compound, target, pathway, and disease data
established by the IMI Open PHACTS project. The protocols annotate phenotypic hit lists and allow follow-
up experiments and mechanistic conclusions. The annotations included are from ChEMBL, ChEBI, GO,
WikiPathways and DisGeNET. Also provided are protocols which select from the IUPHAR/BPS Guide to
PHARMACOLOGY interaction file selective compounds to probe potential targets and a correlation robot
which systematically aims to identify an overlap of active compounds in both the phenotypic as well as any
kinase assay. The protocols are applied to a phenotypic pre-lamin A/C splicing assay selected from the
ChEMBL database to illustrate the process. The computational protocols make use of the Open PHACTS
API and data and are built within the Pipeline Pilot and KNIME workflow tools.
Introduction
Even though the discussion is still ongoing whether or not
phenotypic screening was historically more productive for the
discovery of first in class drugs than target-directed screening,
and whether it continues to do so, it is clear that phenotypic
screening opens new avenues to investigate new cellular
biology.1–4 In the 1970s, phenotypic screening on physiologi-
cal whole animal or organ testing with a limited number of
compounds was very popular and successful. Drug hunters
like Paul Janssen or James Black tested pharmacologically
rich compounds systematically on a broad panel of such phe-
notypic assays across a spectrum of therapeutic areas and dis-
covered breakthrough medicines like antipsychotics, beta-
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blockers, or anti-ulceratives.5 Also, phenotypic screening anal-
ysis of approved drugs can generate new insights. Recently,
Lee et al. screened a large collection of approved drugs in
phenotypic assays including models for osteoporosis, diabetes
and cancer, identifying novel activities for several known
compounds.6
With the fantastic progress in molecular and cellular biol-
ogy, cell-based phenotypic screening in primary or
engineered cell-lines constitutes a promising avenue. New
biology like for instance alternative splicing or translational
read through becomes experimentally accessible using MTS/
HTS approaches. The experiments deliver potentially potent
and specific compounds for which it can be interesting to
elucidate and validate the molecular mechanism. Next to ex-
perimental target validation including chemogenomics pull-
down and knock-in/out experiments, the in silico assessment
of the hit lists constitutes a key step.7–11 This analysis re-
quires a high level of data integration in order for it to be
complete and seamless. Such integration was recently
achieved by the IMI Open PHACTS project12 resulting in the
Open PHACTS Discovery Platform (www.openphacts.org).13
The Open PHACTS project uses semantic web technology for
drug discovery by integrating relevant concept spaces of com-
pound–target–pathway and disease (see Fig. 1 for concepts/
URIs used in this work). This enables, as we will show herein,
insightful interpretation of the phenotypic screening results
to sustain target validation based on hitherto established
drug discovery knowledge.
Here we present six protocols, which could be useful to
annotate the results of a phenotypic screening experiment.
Protocol 1 retrieves known classifications for compounds of
interest. Protocols 1 to 4 retrieve targets, which these com-
pounds have recorded bioactivity values for, and subse-
quently retrieves additional data for these targets (ChEMBL
classification, GO terms, pathways, and diseases, respec-
tively). These protocols are depicted in Fig. 2 and the imple-
mentation of protocol 1 in Pipeline Pilot is shown in Fig. S1.‡
Protocol 5 retrieves all kinases and reported bioactivity values
available in the ChEMBL database and returns an overlap
with the compounds from the phenotypic screening (Fig. 3
and Fig. S2‡). A possibility to join the data retrieved from the
Open PHACTS Discovery Platform with external data is shown
in protocol 6 (Fig. 4 and Fig. S3‡).
Experimental
Software
Workflows were generated first with Pipeline Pilot from BIO-
VIA,14 and were then adapted for KNIME.15 Pipeline Pilot pro-
tocols were created in version 9.2 using version 2.0 of the
Open PHACTS component collection, which was downloaded
from the BIOVIA ScienceCloud Exchange.
KNIME version 2.12.1 with installed JSON (KNIME Labs
Extensions) and REST nodes (KNIME Community Contribu-
tions provided by Cenix BioScience) was used to create the
workflows. Open PHACTS KNIME nodes (org.openphacts.
utils.json_1.1.0) were retrieved from the github repository
(https://github.com/openphacts/OPS-Knime).
Execution of API calls
An overview of API calls used in this study is provided in
Table 1. Documentation of the Open PHACTS API13 is avail-
able at http://dev.openphacts.org/.
Pipeline Pilot. The Open PHACTS component collection
provides one component per API call to facilitate the building
of complex protocols. All components in the collection share
the same logic inside, with the HTTP connector component
performing a GET operation on the appropriate API end-
point. The output hierarchical data is then manipulated
depending on user-defined parameters to extract only the de-
sired parts of the hierarchy which are either flattened using
the flatten hierarchy component or output as hierarchical
data records that can be manipulated further.
Fig. 1 Outline of data showing the links between the different key
identifiers (URI, uniform resource identifiers) assessed for annotation of
compounds and targets in the provided computational protocols. The
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KNIME. API calls were generated using the OPS_Swagger
node (with https://raw.githubusercontent.com/openphacts/
OPS_LinkedDataApi/1.5.0/api-config-files/swagger.json as def-
inition for the calls). A string replacer node was used to up-
date the calls to the latest public version (from 1.5 to 2.0).
Data was retrieved using the GET Resource node and adapted
for a tabular format with the String to JSON and JSON Path
nodes.
Data sources
Calls to the Open PHACTS Discovery Platform were made
with the API version 2.0 (https://dev.openphacts.org/docs/2.0).
Data collected in this study, which was accessed via the Open
PHACTS Discovery Platform, includes ChEMBL16,17 version
20, ChEBI18 release 125, Gene Ontology (GO)19,20 annotations
(accessed Feb. 2015), WikiPathways21 v20151118, and DisG-
eNET22,23 version 2.1.0.
The pre-lamin A/C splicing assay data was selected from
ChEMBL via the Open PHACTS Discovery Platform with the
ChEMBL1293235 target ID (target pharmacology: list call)
and subsequent filtering for the CHEMBL1614310 assay ID.
Protocol 6 includes interaction data from the IUPHAR/BPS





Protocol 1 – ChEBI/ChEMBL annotation and classification.
One of the first questions a medicinal chemist is likely to ask
when receiving a list of compounds from a phenotypic screen
is related to the target classes that the molecules can be ac-
tive against. Are there kinase inhibitors or GPCR ligands in
the hit list and at which potency level? The known SAR of a
given compound is obtained by using the ‘Compound Phar-
macology: List’ API call. Then, two more API calls are needed
for the target and compound annotations. The ‘Target Classi-
fication’ API call enables to retrieve the ChEMBL classifica-
tion for the protein targets of interest by introducing their
URIs as query input parameter. The ‘Compound Classification’
API call enables to retrieve the ChEBI annotation for the
given compounds by introducing their compound URIs as in-
put. For results interpretation, applying simple aggregation
statistics on the number of individual assay activities, indi-
vidual targets, or directly compounds allow to assess the rela-
tive relevance of the findings. Finally, output reports are gen-
erated at both the individual compound–target–activity level
and at the aggregated level (e.g. by grouping according to the
ChEMBL ‘Protein Classification’) (Fig. 2). The ChEBI annota-
tion provides a first overview on the pharmaceutical and
chemical classes covered. All available ChEBI annotation
types are retrieved in the protocols, but especially the func-
tion annotation “has role”, and the chemical class of the mol-
ecule “Type” will be of interest here. This compound annota-
tion facilitates the communication between chemists and
biologists by providing a standardized language.
Protocol 2 – GO annotation. The Gene Ontology (GO) al-
lows the annotation of gene products with molecular func-
tion, biological process, and cellular component information.
The cellular component information captures the localization
of the gene product in the cell, which can be a part of the cell
(e.g. the plasma membrane) or a more specific component
such as a protein complex. The molecular function describes
the activity of the gene product at a molecular level (e.g. cata-
lytic activity), while a biological process is a series of events
that can be composed of several molecular functions.
In the Open PHACTS Discovery Platform, this information
is accessible using again the ‘Target Classification’ API call,
Fig. 3 Schematic overview of protocol 5.
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by inputting the protein target URIs in order to retrieve the
GO classification trees. This information is highly comple-
mentary to the target annotation obtained in protocol 1. The
information on the cellular component can be used to local-
ize the site of action of the compounds provided that the un-
derlying assay data is at the cellular level and not a cell-free
biochemical format. The biological process and molecular
mechanism information is essential for the assessment of
the activities. Again, simple aggregation statistics at the level
of individual assay activities, individual targets, or directly
compounds allow an assessment of the relevance of the infor-
mation. Observing, for instance, multiple highly potent com-
pounds hitting different targets pointing to the same molecu-
lar process builds confidence of the relevance of this process
for the observed phenotype. Given the richness of the GO ter-
minology, its interpretation requires broad knowledge of gen-
eral molecular and cellular biology and disease biology in or-
der to assess the relevance.
Protocol 3 – WikiPathways annotation. Are multiple pro-
tein nodes of the same pathway hit by different compounds?
This is a question of interest to build confidence that the par-
ticular pathway is of relevance for the observed phenotype.
Also, it increases the meaningfulness of the target findings, if
they all contribute to the same phenotypic outcome through
the same process.
Extending the biological knowledge of a hit list is possible
using the WikiPathways annotation. Like in protocol 1 and 2,
the workflow first retrieves the (poly)pharmacology data for
the given compounds, resulting in a list of targets. The use of
the ‘Pathways for Targets List’ API call, which yields to the as-
sociated WikiPathways URIs and Names for an inputted pro-
tein target URI list, gives a pathway-based summarizing view
of the bioactivities.
Protocol 4 – links to diseases and possible side effects –
DisGeNET annotation. Knowledge about the diseases and
side effects potentially associated to the compounds through
the target link is of interest in order to either prioritize hits
with potential synergistic effects or to deprioritize hits associ-
ated with adverse side effects. Also, knowledge about a dis-
ease with strong mechanistic overlap is informative. DisG-
eNET, a database on human diseases and their genes, is
available through the Open PHACTS Discovery Platform.
DisGeNET is one of the most comprehensive resources on
gene-disease associations collected and integrated from a va-
riety of authoritative sources on human genetics and the sci-
entific literature, which covers the whole spectrum of human
Table 1 API calls and input, output and aggregation parameters






List of Compound URIs Cache 1: CompoundID and
URICompound, canonical smiles
Join cache 3 and 2 based on target name;
Join cache 1 on URICompound
Target
Classifications
Cache 2: URI compound, URI assay,
pChembl, TargetName, URITarget
Merge and group on classification




List of Compound URIs Cache 1: CompoundID and
URICompound, canonical smiles
Join cache 2 and 1 based on
URICompound.
Cache 2: URI compound, URI Chebi,
ChebiDescription




List of Compound URI Cache 1: CompoundID and
URICompound, canonical smiles
Join cache 3 and 2 based on target name;
Join cache 1 on URICompound
Pathways for
Target: List
Cache 2: URI compound, URI assay,
pChembl, TargetName, URITarget
Merge and group on PathwayName





List of Compound URIs Cache 1 : CompoundID and
URICompound, canonical smiles
Join cache 3 and 2 based on target name;
Join cache 1 on URICompound
Diseases for
Target: List
Cache 2 : URI compound, URI assay,
pChembl, TargetName, URITarget
Merge and group on DiseaseName
Cache 3 : Target Name, URIDisease,
DiseaseName
To limit the runtime of the protocol
merging is done directly on the data






family key to launch query
Cache 1 : List of 455 human kinases
for which ChEMBL holds data
Join Cache 2 based on INCHIKEY to




Cache 2 : Lamin A/C splicing assay data
6 GtoPdb Box Compound
Pharmacology:
List,
List of Compound URIs.
Cache 1 : Read GtoPdb
interaction file
Cache 2 Keep URITarget and
URIUniprot and extract UniprotID
from URIUniprot
Join cache 1 GtoPdb interaction file to
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diseases. The disease annotations of the targets are retrieved
from the Open PHACTS Discovery Platform via the API call
‘Diseases for Target: List’. The corresponding workflow is
built in a similar manner as protocols 1–3, i.e. combining
data calls and joining operations followed by computation of
aggregation statistics.
Protocol 5 – correlation of the phenotypic and bio-
chemical screening data. Working with phenotypic screening
data, we observe that many hit lists contain a significant
number of kinase inhibitors (E. Jacoby, unpublished results).
This might be the result of the kinase focus of the compound
libraries achieved in the last decade, but might also reflect
the dominant role that kinases use to play in the modulation
and regulation of signalling pathways.25 Additionally, kinase
inhibitors were shown to retrieve active hits in phenotypic
screening assays (NCI-60 panel and angiogenesis).26 One ob-
vious question is therefore to identify potential correlations
between the known kinase assays and the phenotypic assay
of interest. Identified kinases might play a relevant role in
the biological process interrogated by the phenotypic assay.
With the integration achieved in the Open PHACTS Dis-
covery Platform, it is directly feasible to retrieve all kinases
from the ChEMBL classification tree (‘Target Class Member:
List’ call) as well as the connected pharmacological data
(‘Target Pharmacology: List’ call). Alternatively, the ‘Target
Class Pharmacology: List’ call can be used directly. We opt
here to apply the most simple correlation type by analysing
the number of hits in common in the assays to be compared.
The assay correlation robot might obviously be applied to
other target families or to the entire pharmacological space.
This analysis is complementary to the analysis provided in
protocol 1.
Protocol 6 – compound tool box to validate/devalidate
identified potential targets of protocol 1 based on GtoPdb.
GtoPdb provides a list of studied and validated compound in-
teractions from scientific literature. Therefore, compounds
which include probe compounds from the Structural Geno-
mics Consortium (SGC, http://www.thesgc.org) and the Mo-
lecular Libraries and Imaging Program (MLP, http://mli.nih.
gov/mli) can be used as potent and specific tools to validate/
devalidate a potential target in a complementary manner to
CRISPR-Cas9 (ref. 27) technology. The GtoPdb interaction
file, is not yet integrated in the Open PHACTS Discovery Plat-
form. However, due to the adoption of common protein iden-
tifiers (UniProt accessions) between resources, it is possible
to use the ‘Map URL’ API call to retrieve a UniProt URI for
each target based on the protein target URIs and join these
with the GtoPdb interaction file containing compound–target
interactions. In this way it is possible to get for each protein
target of interest an associated compound list for testing.
This application demonstrates the flexibility by combining
the Open PHACTS API and data workflow tools to integrate
additional data sources. The protocol was designed in a man-
ner to distinguish between agonist, antagonist, and other
interaction types and to keep the most potent compound for
each category for each target.
Workflow designs in Pipeline Pilot and KNIME. Given the
technical differences and particularities of the Pipeline Pilot
and KNIME workflow tools there are a number of differences
in the overall architecture of the resulting workflows. Table 1
summarizes the used API calls and input, output and aggre-
gation parameters as used in Pipeline Pilot implementation.
Pipeline Pilot protocols are available from the BIOVIA
ScienceCloud Exchange (https://exchange.sciencecloud.com,
search for keyword ‘openphacts’). The KNIME workflows can
be downloaded from myExperiment,28 a collaborative envi-
ronment for publishing workflows (http://www.
myexperiment.org/packs/707.html).
The Pipeline Pilot implementation makes full usage of the
cache functionality which allows to store data using the API
into data caches and then to join and aggregate it within a
separate data stream. The design of the data pipelining pro-
tocols is made in a manner that at each step selected output
data is cached and only the required input URIs are forward
propagated to the next API calling node (see Fig. S1–S3‡). The
outputs are then joined and grouped in a sequential manner
to produce the desired information. This principle illustrates
a key advantage for data mining. In this approach data is
obtained collectively and the user sorts out and selects the
desired information afterwards. Protocols 1 to 4 were com-
bined into a single workflow in KNIME to reduce calculation
time for redundant steps.
Application to correctors for lamin A splicing assay. In or-
der to demonstrate the capabilities of the protocols, we ap-
plied them to the pre-lamin A/C splicing assay from the
PubChem BioAssay database (AID:1487 (ref. 29)). This
Pubchem assay has the title ‘PUBCHEM_BIOASSAY: Valida-
tion of Assay for Modulators of Lamin A Splicing’ in ChEMBL
(Assay ID CHEMBL1614310) and lists 280 bioactivities for
which 85 different compounds have pChEMBL values ≥5
(containing both mildly active and very active compounds),
which are further analysed hereafter. The assay measures ex-
pression of correctly spliced protein and was generated
within the NIH Molecular Libraries Probe Production Net-
work.30 It aims to identify splicing correctors against the
Hutchinson–Gilford progeria syndrome (HGPS). HGPS is a
paediatric premature aging disease caused by a spontaneous
mutation in the lamin A/C (LMNA) gene. The mutation acti-
vates a cryptic splice site in the LMNA pre-mRNA which re-
sults in production of a pre-lamin A protein that cannot be
processed properly. The mutant protein accumulates in the
nucleus and negatively affects numerous cellular functions.
The resulting data for this application example from the
Pipeline Pilot protocols are provided in the ESI.‡ Investiga-
tion of the target classifications (protocol 1) show that 47 ki-
nase activities are observed based on 8 compounds on 27 tar-
gets. Interesting are the CGMC kinases DYRK1A and GSK3B
and the MAP Kinases p38 α and ß, c-Jun2 and 3 and ERK2.
DYRK1A inhibitors are reported in the literature to modulate
alternative pre-mRNA splicing of model gene transcripts in
cells with submicromolar potencies.31 For the family A GPCR,
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targets. Most prominent are the monoamine receptor activi-
ties. 27 epigenetic regulator activities are observed based on
17 compounds on five targets.
Regarding GO component, 186 terms are found; 13 com-
pounds are linked to the spliceosomal complex via the
heterogeneous nuclear ribonucleoprotein A1 and the survival
motor neuron protein. For GO process, 1287 terms are found.
Multiple compounds are linked to various DNA related pro-
cesses via the Bloom syndrome protein, while 13 compounds
are linked to spliceosomal complex assembly. For GO func-
tion, 340 terms are found. The kinase assay correlation robot
supports the hint to kinases and points to the MAP kinase
ERK2 assay CHEMBL1613808 which has eight compounds in
common. The underlying pathway is the MAPK signalling
pathway, which is found in protocol 3 for 12 targets.
In general, 306 pathways are identified, with ‘GPCR down-
stream signaling’ and ‘GPCR ligand binding’ showing the
highest count of identified targets (19), and ‘FAS pathway
and Stress induction of HSP regulation’ and ‘Integrated Pan-
creatic Cancer Pathway’ showing the highest count of active
molecules (37).
The DisGeNET annotation (protocol 4) provides links to
3631 diseases and side-effects; 89 of them have more than 20
potential efficacy targets links. Various neoplasms and can-
cers are prominent given the link via kinases. Spinal muscu-
lar atrophy is linked by 13 hits via the survival motor protein
link. It will require further disease biology expertise to recog-
nize relevant links to the observed phenotype.
ChEBI terms (protocol 1) associated with at least five com-
pounds include five metabolites and nine antineoplastic
agents among which fluorouracil, camptothecin and rote-
none are listed. Rotenone is discussed in the literature to
modulate splicing of several genes, e.g. alternative splicing
of the X-linked NDUFB11 gene of the respiratory chain com-
plex I.32
The analysis from protocol 6 suggests testing of 79 com-
pounds in the phenotypic screening assay. Very prominent
are monoamine receptor ligands and kinase inhibitors.
After having competed the in silico annotation, an obvious
questions aims towards the modus operandi for follow-up ex-
periments and drug discovery. A first obvious experiment is
to test the tool compounds retrieved from the GtoPdb data-
base in the phenotypic assay to verify if they produce the de-
sired phenotype. Obviously, in vitro target validation through,
for instance, CRISPR/cas9 experiments would complete the
experimental target validation. In a similar perspective,
ChEMBL biological annotations point to targets which enable
such testing. The usage of the results from the correlation ro-
bot opens the possibility to substitute the phenotypic assay
for the mechanistic target based assay for as the primary
screening or optimization assay. This might allow for in-
stance for higher throughput in screening. Given the low
number of common hits found between the MAP kinase
ERK2 assay and the pre-lamin phenotypic assay, we would
recommend to test further ERK2 reference compounds in the
phenotypic assay before taking a decision. A key difficulty re-
lies in making sense of the GO, WikiPathways and DisGeNET
annotations. Given that each putative target pulls potentially
a multitude of these annotation categories, a clear navigation
strategy is missing. One possible way forward could be the
analysis of similarities between the annotations. Further
work and domain expertise is needed to achieve this. Practi-
cally, the hint that 13 compounds are linked to the biology of
the spliceosome complex increases the attractiveness of these
compounds for follow-up chemistry lead optimization. Con-
versely, the link to activity on the Bloom syndrome protein
flags a different set of compounds as potentially problematic,
given the link to genomic instability of this protein.
Conclusions
Knowing the knowns about a phenotypic screening hit list is
a first essential step in the analysis of every phenotypic
screening project and contributes to the validation of the po-
tential efficacy targets associated to the hits.33 Collected
knowledge might help to decide whether the research team
should optimize hit compounds based on a phenotypic read-
out or pursue with mechanistic target based assays. The
interpretation of the provided information requires broad
knowledge of general molecular and cellular biology, as well
as disease biology in order to assess their relevance. Impor-
tantly, this data-driven collected knowledge also guides the
assessment of potential off-biology, including pharmacologi-
cal and toxicological side-effects early in the projects. Herein
presented computational protocols focus on cellular pheno-
typic screening data where the link to molecular mechanisms
is possible.
A limitation of the here presented analysis could be a bias
in the available data in the public domain databases used. In
Open PHACTS we mainly use one data source for each of the
data types (e.g. ChEMBL for bioactivities, DisGeNET for Dis-
eases, WikiPathways for pathways). While most of these
sources combine data from several places, this could lead to
a bias in the data. The illustrated analyses will benefit from
the inclusion of data beyond the Open PHACTS Discovery
Platform, as for instance commercial data sources (like
GOStar from GVKbio34) or patent extracted data (like
SureChEMBL35). Additionally, API calls to other available data
sources (e.g. the Entrez Utilities API Eutils) could be inte-
grated into the protocols, to increase the coverage of the
returned data. The corporate internal SAR data stores with
massive amounts of fulldeck screening data will not only en-
able to include proprietary compounds into the analysis, but
also to have access to more complete SAR data matrices. This
will be of benefit especially for correlation analyses. The in-
clusion of negative screening results becomes equally possi-
ble with the corporate in house data. Negative data is of par-
ticular value given that the identified target proteins for
phenotypic negatives cannot be dominant phenotypic targets.
This is a very important point. In a typical in silico
deconvolution effort, many active compounds will point to
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to generic pathways, e.g. ‘GPCR downstream signaling’. How-
ever, when putting these activities into context and showing
that a similar or greater percentage of phenotypically inactive
compounds are also hitting these targets, they can be re-
moved from the list of potentially interesting efficacy targets.
At this stage a rigorous statistical analysis will enable to dis-
tinguish a real signal from noise and help to interpret the re-
sults. It will thus be relevant to store the inactives of a pheno-
typic screen to enable such analysis.
Further restrictions on the suggested targets might appear
from the inclusion of gene expression data. This is already
feasible with the Open PHACTS Discovery Platform. The inclu-
sion of protein complex information offers an equally inter-
esting extension possibility of the pathway analysis protocol
3. A relevant question is: are multiple members of a given
functional complex hit by different compounds? This aspect
can be in part addressed by the GO cellular component anno-
tation. Also, a combination of pathway and disease informa-
tion could be worthwhile, to investigate the overlap of both.
Extending beyond the known knowns is possible by apply-
ing predictive chemogenomics SAR models which are cur-
rently being developed in academia and industry.37–40 Espe-
cially noteworthy are the predictive inference capabilities
intrinsic to semantic approaches which allow integrating sim-
ilarities among the data. Similarities between compounds, as
well as similarities between proteins at the sequence level or
even binding site level, can directly be coded in RDF. An ex-
tended version of the protocols, integrating experimental and
predicted data would obviously top rank targets for which
there is experimental evidence, and then, highlight the addi-
tional conclusions drawn from the predictions. The added
value of the predictions is to potentially extend to the discov-
ery of novel targets, not belonging to the known knowns.
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